DV
Dividend Vision

SVRA Stock — Savara Inc

Savara Inc (SVRA)

Updated October 16, 2026.

SVRA is a Stock. Total return is -99.7% over the past 29.9 years, 1723.7 points behind SPY at 1624.0%.

Savara Inc. is a clinical-stage biopharmaceutical company developing treatments for rare respiratory diseases, with its lead candidate molgramostim in Phase 3 testing for autoimmune pulmonary alveolar proteinosis. The company does not currently distribute dividends. This security appeals primarily to investors seeking exposure to early-stage drug development rather than those focused on generating income.

SVRA dividend yield and income

Price as of 2026-10-16.

The payment date is 04/28/2017.

SVRA performance versus SPY

Price and return data through 2026-10-16.

Total return is -99.7% over the past 29.9 years, 1723.7 points behind SPY at 1624.0%. Over the past year its total return — price change plus distributions reinvested — is 24.3%. Its deepest 1-year drawdown was 35.9%.

WindowTotal returnCAGR
1M-13.3%—
3M-19.4%—
6M-21.1%—
YTD-26.2%—
1Y24.3%—
2Y CAGR—9.10%
3Y CAGR—8.20%
5Y CAGR—28.10%
10Y CAGR—-2.30%
Since inception (29.9 years)-99.7%-18.10%

SVRA key facts

Asset type
Stock
Asset class
Equity
Inception date
11/18/1996
Distribution frequency
None
Last close
$4.45 (as of 2026-10-16)
Market cap
$914,297,067
Average volume
2232255.0
Payment date
04/28/2017
Beta
0.199
Payout ratio
0.0%
Forward P/E
0.4076
EPS
$-0.58

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

SVRA risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 35.9%.

Who may consider SVRA — and who may not

It is a weaker fit for investors who need monthly cash flow (SVRA does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on SVRA

Tagged: Healthcare.

Frequently asked questions

Does SVRA pay monthly?

No. SVRA does not currently distribute.

When does SVRA pay a dividend?

SVRA does not currently distribute. The payment date is 04/28/2017.

How has SVRA performed?

Total return is -99.7% over the past 29.9 years, 1723.7 points behind SPY at 1624.0%. Over the past year its total return — price change plus distributions reinvested — is 24.3%. Its deepest 1-year drawdown was 35.9%.

DividendVision analysis is generated from public SEC filing data and may not capture every change. Review the original filing for complete information.